Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Oct;62(4):637–642. doi: 10.1038/bjc.1990.345

Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.

R P Moseley 1, A G Davies 1, R B Richardson 1, M Zalutsky 1, S Carrell 1, J Fabre 1, N Slack 1, J Bullimore 1, B Pizer 1, V Papanastassiou 1, et al.
PMCID: PMC1971477  PMID: 2223581

Abstract

Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.

Full text

PDF
637

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan P. M., Garson J. A., Harper E. I., Asser U., Coakham H. B., Brownell B., Kemshead J. T. Biological characterization and clinical applications of a monoclonal antibody recognizing an antigen restricted to neuroectodermal tissues. Int J Cancer. 1983 May 15;31(5):591–598. doi: 10.1002/ijc.2910310510. [DOI] [PubMed] [Google Scholar]
  2. Azzarelli V., Roessmann U. Pathogenesis of central nervous system infiltration in acute leukemia. Arch Pathol Lab Med. 1977 Apr;101(4):203–205. [PubMed] [Google Scholar]
  3. Bourdon M. A., Wikstrand C. J., Furthmayr H., Matthews T. J., Bigner D. D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983 Jun;43(6):2796–2805. [PubMed] [Google Scholar]
  4. Bourne S., Pemberton L., Moseley R., Lashford L. S., Coakham H. B., Kemshead J. T. Monoclonal antibodies M340 and UJ181.4 recognize antigens associated with primitive neuroectodermal tumours/tissues. Hybridoma. 1989 Aug;8(4):415–426. doi: 10.1089/hyb.1989.8.415. [DOI] [PubMed] [Google Scholar]
  5. Buraggi G. L., Callegaro L., Mariani G., Turrin A., Cascinelli N., Attili A., Bombardieri E., Terno G., Plassio G., Dovis M. Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments. Cancer Res. 1985 Jul;45(7):3378–3387. [PubMed] [Google Scholar]
  6. Carrasquillo J. A., Krohn K. A., Beaumier P., McGuffin R. W., Brown J. P., Hellström K. E., Hellström I., Larson S. M. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep. 1984 Jan;68(1):317–328. [PubMed] [Google Scholar]
  7. Carrel S., Accolla R. S., Carmagnola A. L., Mach J. P. Common human melanoma-associated antigen(s) detected by monoclonal antibodies. Cancer Res. 1980 Jul;40(7):2523–2528. [PubMed] [Google Scholar]
  8. Chessells J. M. Cranial irradiation in childhood lymphoblastic leukemia: time for reappraisal. Br Med J (Clin Res Ed) 1985 Sep 14;291(6497):686–687. doi: 10.1136/bmj.291.6497.686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cheung N. K., Lazarus H., Miraldi F. D., Abramowsky C. R., Kallick S., Saarinen U. M., Spitzer T., Strandjord S. E., Coccia P. F., Berger N. A. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987 Sep;5(9):1430–1440. doi: 10.1200/JCO.1987.5.9.1430. [DOI] [PubMed] [Google Scholar]
  10. Courtenay-Luck N. S., Epenetos A. A., Moore R., Larche M., Pectasides D., Dhokia B., Ritter M. A. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 1986 Dec;46(12 Pt 1):6489–6493. [PubMed] [Google Scholar]
  11. Cumberlin R. L., Luk K. H., Wara W. M., Sheline G. E., Wilson C. B. Medulloblastoma: treatment results and effect on normal tissues. Cancer. 1979 Mar;43(3):1014–1020. doi: 10.1002/1097-0142(197903)43:3<1014::aid-cncr2820430334>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  12. Dalchau R., Fabre J. W. Identification with a monoclonal antibody of a predominantly B lymphocyte-specific determinant of the human leukocyte common antigen. Evidence for structural and possible functional diversity of the human leukocyte common molecule. J Exp Med. 1981 Apr 1;153(4):753–765. doi: 10.1084/jem.153.4.753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Embleton M. J., Rowland G. F., Simmonds R. G., Jacobs E., Marsden C. H., Baldwin R. W. Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate. Br J Cancer. 1983 Jan;47(1):43–49. doi: 10.1038/bjc.1983.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Epenetos A. A., Munro A. J., Stewart S., Rampling R., Lambert H. E., McKenzie C. G., Soutter P., Rahemtulla A., Hooker G., Sivolapenko G. B. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol. 1987 Dec;5(12):1890–1899. doi: 10.1200/JCO.1987.5.12.1890. [DOI] [PubMed] [Google Scholar]
  15. Esteban J. M., Colcher D., Sugarbaker P., Carrasquillo J. A., Bryant G., Thor A., Reynolds J. C., Larson S. M., Schlom J. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer. 1987 Jan 15;39(1):50–59. doi: 10.1002/ijc.2910390110. [DOI] [PubMed] [Google Scholar]
  16. Goldenberg D. M., Preston D. F., Primus F. J., Hansen H. J. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res. 1974 Jan;34(1):1–9. [PubMed] [Google Scholar]
  17. Hitchins R. N., Bell D. R., Woods R. L., Levi J. A. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987 Oct;5(10):1655–1662. doi: 10.1200/JCO.1987.5.10.1655. [DOI] [PubMed] [Google Scholar]
  18. Humm J. L. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986 Sep;27(9):1490–1497. [PubMed] [Google Scholar]
  19. Jansen F. K., Blythman H. E., Carrière D., Casellas P., Gros O., Gros P., Laurent J. C., Paolucci F., Pau B., Poncelet P. Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev. 1982;62:185–216. doi: 10.1111/j.1600-065x.1982.tb00394.x. [DOI] [PubMed] [Google Scholar]
  20. Kulkarni P. N., Blair A. H., Ghose T. I. Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo. Cancer Res. 1981 Jul;41(7):2700–2706. [PubMed] [Google Scholar]
  21. Larson S. M., Carrasquillo J. A., Krohn K. A., Brown J. P., McGuffin R. W., Ferens J. M., Graham M. M., Hill L. D., Beaumier P. L., Hellström K. E. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest. 1983 Dec;72(6):2101–2114. doi: 10.1172/JCI111175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lashford L. S., Davies A. G., Richardson R. B., Bourne S. P., Bullimore J. A., Eckert H., Kemshead J. T., Coakham H. B. A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer. 1988 Mar 1;61(5):857–868. doi: 10.1002/1097-0142(19880301)61:5<857::aid-cncr2820610502>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  23. Miller R. A., Oseroff A. R., Stratte P. T., Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood. 1983 Nov;62(5):988–995. [PubMed] [Google Scholar]
  24. Olson M. E., Chernik N. L., Posner J. B. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol. 1974 Feb;30(2):122–137. doi: 10.1001/archneur.1974.00490320010002. [DOI] [PubMed] [Google Scholar]
  25. Ongerboer de Visser B. W., Somers R., Nooyen W. H., van Heerde P., Hart A. A., McVie J. G. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology. 1983 Dec;33(12):1565–1572. doi: 10.1212/wnl.33.12.1565. [DOI] [PubMed] [Google Scholar]
  26. Primus F. J., Macdonald R., Goldenberg D. M., Hansen H. J. Localization of GW-39 human tumors in hamsters by affinity-purified antibody to carcinoembryonic antigen. Cancer Res. 1977 May;37(5):1544–1547. [PubMed] [Google Scholar]
  27. Taylor-Papadimitriou J., Peterson J. A., Arklie J., Burchell J., Ceriani R. L., Bodmer W. F. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer. 1981 Jul 15;28(1):17–21. doi: 10.1002/ijc.2910280104. [DOI] [PubMed] [Google Scholar]
  28. Thorpe P. E., Brown A. N., Bremner J. A., Jr, Foxwell B. M., Stirpe F. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J Natl Cancer Inst. 1985 Jul;75(1):151–159. [PubMed] [Google Scholar]
  29. Vaughan A. T., Anderson P., Dykes P. W., Chapman C. E., Bradwell A. R. Limitations to the killing of tumours using radiolabelled antibodies. Br J Radiol. 1987 Jun;60(714):567–572. doi: 10.1259/0007-1285-60-714-567. [DOI] [PubMed] [Google Scholar]
  30. Zalutsky M. R., Moseley R. P., Coakham H. B., Coleman R. E., Bigner D. D. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 1989 May 15;49(10):2807–2813. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES